Integrated analysis of cervical squamous cell carcinoma cohorts from three continents reveals conserved subtypes of prognostic significance
-
Published:2022-10-07
Issue:1
Volume:13
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Chakravarthy Ankur, Reddin IanORCID, Henderson StephenORCID, Dong Cindy, Kirkwood Nerissa, Jeyakumar Maxmilan, Rodriguez Daniela RothschildORCID, Martinez Natalia GonzalezORCID, McDermott Jacqueline, Su Xiaoping, Egawa Nagayasau, Fjeldbo Christina S., Skingen Vilde EideORCID, Lyng HeidiORCID, Halle Mari Kyllesø, Krakstad CamillaORCID, Soleiman Afschin, Sprung Susanne, Lechner MattORCID, Ellis Peter J. I.ORCID, Wass MarkORCID, Michaelis MartinORCID, Fiegl HeidiORCID, Salvesen Helga, Thomas Gareth J.ORCID, Doorbar John, Chester KerryORCID, Feber AndrewORCID, Fenton Tim R.ORCID
Abstract
AbstractHuman papillomavirus (HPV)-associated cervical cancer is a leading cause of cancer deaths in women. Here we present an integrated multi-omic analysis of 643 cervical squamous cell carcinomas (CSCC, the most common histological variant of cervical cancer), representing patient populations from the USA, Europe and Sub-Saharan Africa and identify two CSCC subtypes (C1 and C2) with differing prognosis. C1 and C2 tumours can be driven by either of the two most common HPV types in cervical cancer (16 and 18) and while HPV16 and HPV18 are overrepresented among C1 and C2 tumours respectively, the prognostic difference between groups is not due to HPV type. C2 tumours, which comprise approximately 20% of CSCCs across these cohorts, display distinct genomic alterations, including loss or mutation of the STK11 tumour suppressor gene, increased expression of several immune checkpoint genes and differences in the tumour immune microenvironment that may explain the shorter survival associated with this group. In conclusion, we identify two therapy-relevant CSCC subtypes that share the same defining characteristics across three geographically diverse cohorts.
Funder
RCUK | Medical Research Council Prostate Cancer UK RCUK | Biotechnology and Biological Sciences Research Council Cancer Research UK The Debbie Fund (UCLH Charity fund 1427) The Rosetrees Trust
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry,Multidisciplinary
Reference119 articles.
1. de Martel, C., Plummer, M., Vignat, J. & Franceschi, S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J. Cancer 141, 664–670 (2017). 2. Li, N., Franceschi, S., Howell-Jones, R., Snijders, P. J. F., & Clifford, G. M. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J. Cancer 128, 927–935 (2011). 3. Guan, P. et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J. Cancer 131, 2349–2359 (2012). 4. Sand, F. L. et al. Risk of CIN3 or worse with persistence of 13 individual oncogenic HPV types. Int J. Cancer 144, 1975–1982 (2019). 5. Jung, E. J. et al. Cervical adenocarcinoma has a poorer prognosis and a higher propensity for distant recurrence than squamous cell carcinoma. Int. J. Gynecol. Cancer 27, 1228–1236 (2017).
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|